RESUMEN
Ulvan was the polysaccharide (U) from a large edible green algae Ulva pertusa. In this study, phosphorylated ulvan (PU) was prepared by the sodium trimetaphosphate -sodium tripolyphosphate method. Antioxidant and antihyperlipidemic effects of U and PU were investigated employing in vivo systems. The PU was confirmed by IR, 31P NMR and 13C NMR spectra. And in addition, we found that the PU3 group at the dose of 500 mg/kg showed stronger antioxidant activity. Compared with hyperlipidemia group, it significantly increased GSH-Px (34.29%; P < 0.01), SOD (20.04%; P < 0.01) and CAT (37.49%; P < 0.01). Treatment of hyperlipidemia mice with PU resulted in a significant decrease in TC, TG and LDL-C, and significant increase in HDL-C. The PU3 significantly increased HDL-C (33.70%; P < 0.01), decreased LDL-C (52.73%; P < 0.01) and TG (33.58%; P < 0.01) compared with hyperlipidemia group. The result showed that phosphorylation could improve hypolipidaemic and antioxidant activities in vivo. PU may be used as a drug for hyperlipidaemia treatment.
Asunto(s)
Antioxidantes/química , Hipolipemiantes/química , Extractos Vegetales/química , Polisacáridos/química , Ulva/química , Animales , Antioxidantes/farmacología , Peso Corporal , China , Hiperlipidemias/tratamiento farmacológico , Hipolipemiantes/farmacología , Masculino , Ratones , Peso Molecular , Fosforilación , Extractos Vegetales/farmacocinéticaRESUMEN
In this study, purification of polysaccharide ulvan by anion exchange chromatography was prepared, and the major polysaccharide fraction (FU) was collected at 1.0â¯M NaCl elute by anion exchange chromatography, then high sulfate content purified ulvan (HFU) was prepared with sulfur trioxide/N,N-dimethylformamide (SO3-DMF) in formamide. The antioxidant activity and the antihyperlipidemic activity of HFU in mice were determined. The results showed that treatment with HFU could improve the antioxidant and antihyperlipidemic activity. Compared with the hyperlipidemic group, the antihyperlipidemic activity of HFU (125â¯mg/kg) was the strongest, TC concentrations were significantly decreased by 26.7% (Pâ¯<â¯.01), significantly reduced LDL-C (32.6%, Pâ¯<â¯.01), significantly increased HDL-C (19.6%, Pâ¯<â¯.01), and HFU-treated group (250â¯mg/kg) exhibited optimal effects on TG (29.0%, Pâ¯<â¯.01); the HFU groups at the doses of 125â¯mg/kg could significantly decrease the MDA (29.9%, Pâ¯<â¯.01); the HFU groups at the doses of 500â¯mg/kg could increase the activities of GSH-Px obviously (19.9%, Pâ¯<â¯.01).